Streetbeat News

COEP

Coeptis Therapeutics Holdings Inc

Industry

Research and Development in Biotechnology (except Nanobiotechnology)

Open

10.50

Mkt cap

36M

Volume

35K

High

11.40

P/E Ratio

-1.98

52-wk high

13.70

Low

10.50

Div yield

N/A

52-wk low

2.31

Coeptis Therapeutics has secured global rights to the GEAR™ Cell Therapy Platform, forming GEAR Therapeutics to advance NK cell therapies for cancer.

Portfolio Pulse from

March 11, 2025 | 12:45 pm

COEPTIS NexGenAI Affiliates Network has partnered with MarketLeverage to enhance AI-powered affiliate marketing. This collaboration provides COEPTIS with advanced AI tools and access to a vast network of advertisers and publishers.

Portfolio Pulse from

February 20, 2025 | 12:45 pm

Portfolio Pulse from

February 19, 2025 | 9:15 pm

COEPTIS, Inc. has launched COEP Venture Group to invest in AI, RPA, and AI Agent startups, aiming to accelerate technology advancements in these fields.

Portfolio Pulse from

February 13, 2025 | 2:00 pm

COEPTIS, Inc. (Nasdaq: COEP) has completed a $10 million Series A Preferred Financing Round, emphasizing its focus on technological innovation and AI integration in biotechnology solutions.

Portfolio Pulse from

February 06, 2025 | 1:30 pm

Coeptis Therapeutics Holdings has rebranded to COEPTIS, signaling a strategic shift towards technology and artificial intelligence, beyond its traditional biopharmaceutical focus. This move highlights the company's commitment to innovation and shareholder value.

Portfolio Pulse from

January 30, 2025 | 1:45 pm

Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) has announced the first customer adoptions of its NexGenAI Marketing Platform, securing five new clients with a total contract value of $1.7 million. This marks a significant step in AI-driven marketing innovations in the biopharma sector for Coeptis.

Portfolio Pulse from

January 07, 2025 | 1:15 pm

Coeptis Therapeutics Holdings, Inc. announced a 1-for-20 reverse stock split of its common stock, following board and majority stockholder approval. This move is part of a strategy to adjust the company's stock structure.

Portfolio Pulse from

December 27, 2024 | 1:30 pm

Coeptis Therapeutics Holdings, Inc. has acquired the NexGenAI Affiliates Network platform and launched Coeptis Technologies, aiming to integrate AI innovation into biotechnology and technology sectors.

Portfolio Pulse from

December 26, 2024 | 1:30 pm

Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) has executed a Binding Letter of Intent to acquire NexGenAI Affiliates Network, enhancing its capabilities with AI-powered marketing and robotic process automation. This acquisition aims to drive innovation, operational efficiency, and growth opportunities.

Portfolio Pulse from

December 03, 2024 | 1:30 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.